Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab combinations in advanced NSCLC
NCT03064854Phase 1Terminated
- Sponsor
- Novartis
- Start
- May 2017
- Primary completion
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 12
01
Overview
Phase 1, open-label trial of spartalizumab in non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 42 days and Overall Response Rate at 28 months. Started May 2017; status: terminated.
02
Drugs
spartalizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03064854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03064854.